Intramuscular anti-D in chronic immune thrombocytopenia children with severe thrombocytopenia

Area of Science:

• Pediatrics
• Hematology
• Immunology

Background:

• Chronic immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet counts.
• Severe thrombocytopenia in children poses a significant bleeding risk.
• Intravenous (IV) anti-D is a known treatment, but its availability can be limited.

Purpose of the Study:

• To evaluate the efficacy of intramuscular (IM) anti-D in raising platelet counts in children with chronic ITP.
• To assess the safety and response rates of a phased IM anti-D regimen.

Main Methods:

• Nine pediatric patients with chronic ITP and platelet counts <20 × 10(9)/L received IM anti-D (10 mcg/kg/dose) in three phases.
• Phase 1: Daily for 5 days. Phase 2: Weekly for 12 weeks (withheld if platelets ≥ 20 × 10(9)/L). Phase 3: Every 2 weeks for 24 weeks.
• Response defined by International Working Group criteria.

Main Results:

• Phase 1 showed a 66.7% response rate.
• Subsequent phases (2 and 3) had response rates of 11.1% and 7.7% respectively, over total follow-up episodes.
• The treatment was generally well-tolerated, with specific response rates varying across treatment phases.

Conclusions:

• A 5-day course of IM anti-D at 10 mcg/kg is a viable alternative for increasing platelet counts in children with severe chronic ITP.
• This regimen provides a crucial treatment option when IV anti-D is not accessible.
• Further research may explore optimal dosing and long-term efficacy.